PGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Progenics Pharmaceuticals Inc's account receivable for the three months ended in Mar. 2016 was $2.43 Mil. Progenics Pharmaceuticals Inc's revenue for the three months ended in Mar. 2016 was $2.45 Mil. Hence, Progenics Pharmaceuticals Inc's days sales outstanding for the three months ended in Mar. 2016 was 90.65.
During the past 13 years, Progenics Pharmaceuticals Inc's highest Days Sales Outstanding was 180.24. The lowest was 0.36. And the median was 32.86.
Progenics Pharmaceuticals Inc's days sales outstanding increased from Mar. 2015 (55.93) to Mar. 2016 (90.65).
Days sales outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Account receivable can be measured by Days Sales Outstanding.
Progenics Pharmaceuticals Inc's Days Sales Outstanding for the fiscal year that ended in Dec. 2015 is calculated as
Progenics Pharmaceuticals Inc's Days Sales Outstanding for the quarter that ended in Mar. 2016 is calculated as:
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Progenics Pharmaceuticals Inc Annual Data
Progenics Pharmaceuticals Inc Quarterly Data